Calliditas Therapeutics shares are trading lower after the company reported Q2 financial results and issued FY23 net sales results.
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics reported its Q2 financial results and issued FY23 net sales results, which led to a decrease in its share price.
August 17, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Calliditas Therapeutics' shares are trading lower after the company reported its Q2 financial results and issued FY23 net sales results.
The decrease in Calliditas Therapeutics' share price is likely due to the company's Q2 financial results and FY23 net sales results not meeting market expectations. This news directly impacts the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100